Communiqués Kodiak Sciences Inc.

Actions

KOD

US50015M1099

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 05/07/2024			Varia. 5j.	Varia. 1 janv.
2,35 ^USD	+6,82%		0,00%	-22,70%

13/06	Transcript : Kodiak Sciences Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 08:00 AM
15/05	Kodiak Sciences Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences	29/05	PR
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results	15/05	PR
Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	15/05	AQ
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy	14/05	PR
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform	02/05	PR
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	28/03	PR
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024	26/03	PR
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting	30/01	PR
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference	04/01	PR
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference	21/11	PR
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights	14/11	PR
Diabetic Retinopathy Pipeline, Clinical Trials, and Key Companies - Ocular Therapeutics , Novartis, Bayer	30/10/23	AQ
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society	11/10/23	PR
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference	11/09/23	AQ
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference	08/09/23	PR
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion	07/09/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD	19/08/23	PR
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights	15/08/23	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD	10/08/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD	05/08/23	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Kodiak Sciences Inc.

Actions

KOD

US50015M1099

Communiqués

Filtres